FDA - Potential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS) July - September 2010

Benzonatate (Tessalon)
Dronedarone hydrochloride (Multaq)
Epoetin alfa (Epogen/Procrit)
Gemcitabine hydrochloride (Gemzar)
Lanreotide acetate (Somatuline depot)
Lanthanum carbonate (Fosrenol)
Levetiracetam (Keppra)
Lopinavir/Ritonavir oral solution (Kaletra)
Octagam 5%, Immune Globulin Intravenous (Human)
Pioglitazone HCl (Actos)
Ranolazine (Ranexa)
Sodium oxybate (Xyrem) 
Source